SE440079B - Substituerade 5-(2-imidazolin-2-yl)-aminopyrimidiner och farmaceutisk komposition - Google Patents

Substituerade 5-(2-imidazolin-2-yl)-aminopyrimidiner och farmaceutisk komposition

Info

Publication number
SE440079B
SE440079B SE7909392A SE7909392A SE440079B SE 440079 B SE440079 B SE 440079B SE 7909392 A SE7909392 A SE 7909392A SE 7909392 A SE7909392 A SE 7909392A SE 440079 B SE440079 B SE 440079B
Authority
SE
Sweden
Prior art keywords
imidazolin
aminopyrimidine
methyl
melting point
blood pressure
Prior art date
Application number
SE7909392A
Other languages
English (en)
Swedish (sv)
Other versions
SE7909392L (sv
Inventor
W Stenzel
E Cohnen
W Fleck
B Armah
Original Assignee
Beiersdorf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2849537A external-priority patent/DE2849537C2/de
Priority claimed from DE19792937023 external-priority patent/DE2937023A1/de
Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag
Publication of SE7909392L publication Critical patent/SE7909392L/xx
Publication of SE440079B publication Critical patent/SE440079B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE7909392A 1978-11-15 1979-11-14 Substituerade 5-(2-imidazolin-2-yl)-aminopyrimidiner och farmaceutisk komposition SE440079B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2849537A DE2849537C2 (de) 1978-11-15 1978-11-15 Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE19792937023 DE2937023A1 (de) 1979-09-13 1979-09-13 Neue substituierte 5-(2-imidazolin-2-yl)-aminopyrimidine und verfahren zu deren herstellung

Publications (2)

Publication Number Publication Date
SE7909392L SE7909392L (sv) 1980-05-16
SE440079B true SE440079B (sv) 1985-07-15

Family

ID=25776489

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7909392A SE440079B (sv) 1978-11-15 1979-11-14 Substituerade 5-(2-imidazolin-2-yl)-aminopyrimidiner och farmaceutisk komposition

Country Status (12)

Country Link
US (1) US4323570A (da)
AT (1) AT374197B (da)
AU (1) AU541305B1 (da)
CA (1) CA1138454A (da)
CH (1) CH642965A5 (da)
DK (1) DK150142C (da)
ES (1) ES486349A1 (da)
FR (1) FR2441625A1 (da)
GB (1) GB2039275B (da)
IT (1) IT1127225B (da)
NL (2) NL190553C (da)
SE (1) SE440079B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2146986B (en) * 1983-09-23 1987-06-17 Lilly Co Eli Process for preparing 5-substituted pyrimidines
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
DE3739779A1 (de) * 1987-11-24 1989-06-08 Beiersdorf Ag Pharmazeutische praeparate
DE3904795C2 (de) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmazeutisches Präparat und dessen Verwendung
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel
US5972948A (en) * 1994-07-01 1999-10-26 Solvay Pharmaceuticals Gmbh Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
US5977121A (en) * 1995-02-28 1999-11-02 Eli Lilly And Company Use of moxonidine for the treatment of atherosclerosis
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
TR199802496T2 (xx) * 1996-06-06 1999-02-22 Eli Lilly And Company Konjestif kalp yetmezli�ini tedavi i�in form�lasyon.
NO980546L (no) * 1997-02-11 1998-08-12 Lilly Co Eli Farmas°ytiske midler
DE19722322A1 (de) * 1997-05-28 1998-12-03 Solvay Pharm Gmbh Nephroprotektives Arzneimittel
EP0954316A4 (en) * 1997-09-03 2002-02-13 Lilly Co Eli PYRIMIDINE DERIVATIVES
DE19911371A1 (de) 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
AU2003257418A1 (en) * 2002-06-19 2004-01-06 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
JP2009524619A (ja) * 2006-01-27 2009-07-02 エフ.ホフマン−ラ ロシュ アーゲー Cns障害の処置のための2−イミダゾールの使用
ATE407931T1 (de) 2006-06-26 2008-09-15 Chemagis Ltd Verbessertes verfahren zur herstellung von moxonidine
DE602006003204D1 (de) * 2006-06-26 2008-11-27 Chemagis Ltd Reinigungsverfahren von Moxonidine
EP1894926A1 (en) * 2006-06-26 2008-03-05 Chemagis Ltd. Polymorphs of moxonidine and processes for preparation therefor
EP2054391A4 (en) * 2006-08-17 2009-08-26 Chemagis Ltd A SINGLE TAUTOMER-CONTAINING CRYSTALLINE MOXONIDINE AND METHOD FOR THE PRODUCTION THEREOF
EP1894927B1 (en) * 2006-08-31 2010-11-10 Chemagis Ltd. The use of moxonidine salts for purification of moxonidine
BRPI0718059A2 (pt) * 2006-10-19 2013-11-05 Holffmann La Roche Ag F Aminometil-2-imidazóis com afinidade com os receptores amina-associado traço
MX2009003801A (es) * 2006-10-19 2009-04-22 Hoffmann La Roche Aminometil-4-imidazoles.
BRPI0718054A2 (pt) * 2006-11-02 2013-11-05 Hoffmann La Roche 2-imidazóis substituídos como moduladores de receptores associados à traços de aminas
AU2007321376A1 (en) * 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
WO2008073125A1 (en) * 2006-12-12 2008-06-19 Chemagis Ltd. Moxonidine analogs, preparation processes and uses therefor
WO2008071574A1 (en) * 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2 -imidazoles as ligands for trace amine associated receptors (taar)
US20080146523A1 (en) * 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
CA2675221C (en) * 2007-02-02 2016-02-23 F. Hoffmann-La Roche Ag Novel 2-aminooxazolines as taar1 ligands
MX2009008465A (es) * 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
CA2691082A1 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (taars)
BRPI0812833A2 (pt) * 2007-07-03 2014-12-09 Hoffmann La Roche 4-imidazolinas e seu uso como antidepressivos
KR101133862B1 (ko) * 2007-07-27 2012-04-06 에프. 호프만-라 로슈 아게 Taar 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민
CN101765425A (zh) * 2007-08-02 2010-06-30 弗·哈夫曼-拉罗切有限公司 苯甲酰胺衍生物用于治疗cns障碍的用途
CA2695331A1 (en) * 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
ES2556633T3 (es) * 2008-07-24 2016-01-19 F. Hoffmann-La Roche Ag Derivados de 4,5-dihidro-oxazol-2-ilo
US8242153B2 (en) * 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US20100311798A1 (en) * 2009-06-05 2010-12-09 Decoret Guillaume 2-aminooxazolines as taar1 ligands
US8354441B2 (en) * 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
EP2586779A1 (en) 2011-10-24 2013-05-01 Hetero Research Foundation Process for the preparation of moxonidine
DE102012215896A1 (de) 2012-09-07 2014-03-13 Wörwag Pharma GmbH & Co.KG Moxonidinsynthese mit Hilfe organischer Basen
ES2608004T3 (es) 2012-12-03 2017-04-05 WÖRWAG PHARMA GmbH & Co. KG Método mediante catálisis por transferencia de fase
EP2765131B1 (en) 2013-02-08 2016-11-23 Arevipharma GmbH Process for the production of Moxonidine
EP2970214A1 (en) * 2013-03-14 2016-01-20 Farmak, A.S. Improved process for the manufacture of moxonidine
EP2829540A1 (en) 2013-07-26 2015-01-28 Abbott Healthcare Products B.V. Synthesis of substituted aminopyridines
CA2920856C (en) 2013-08-09 2026-03-03 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
RS60825B1 (sr) 2016-03-17 2020-10-30 Hoffmann La Roche Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a
GB202103400D0 (en) * 2021-03-11 2021-04-28 3Z Ehf Novel treatments
EP4243826A1 (en) 2020-11-12 2023-09-20 3Z Ehf Novel treatments of attention deficit/hyperactivity disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754832A (fr) 1969-08-14 1971-02-15 Beecham Group Ltd Iminazolines
GB1319840A (en) * 1970-08-27 1973-06-13 Beecham Group Ltd Substituted 5-amino imidazoles
BE795636A (fr) * 1972-02-19 1973-08-20 Schering Ag Nitroimidazolylpyrimidines, et leur procede de preparation
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
DE2220906A1 (de) * 1972-04-28 1973-11-15 Boehringer Sohn Ingelheim Neue substituierte 2-phenylaminoimidazoline-(2), deren saeureadditionssalze sowie verfahren zu deren herstellung
BE503170A (da) * 1975-09-02

Also Published As

Publication number Publication date
NL190553B (nl) 1993-11-16
IT7927284A0 (it) 1979-11-14
NL7908192A (nl) 1980-05-19
IT1127225B (it) 1986-05-21
CA1138454A (en) 1982-12-28
CH642965A5 (de) 1984-05-15
SE7909392L (sv) 1980-05-16
DK150142B (da) 1986-12-15
AT374197B (de) 1984-03-26
NL940011I1 (nl) 1994-08-01
GB2039275A (en) 1980-08-06
US4323570A (en) 1982-04-06
FR2441625B1 (da) 1981-12-31
ATA727079A (de) 1983-08-15
NL190553C (nl) 1994-04-18
ES486349A1 (es) 1980-06-16
FR2441625A1 (fr) 1980-06-13
AU541305B1 (en) 1985-01-03
DK150142C (da) 1987-06-01
DK481879A (da) 1980-05-16
NL940011I2 (nl) 1998-05-06
GB2039275B (en) 1982-11-17

Similar Documents

Publication Publication Date Title
US4323570A (en) Substituted aminopyrimidines
CA2014457C (en) Pyrimidine derivatives
US4746664A (en) Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
US3211731A (en) Pyrazolo-pyrimidines and process for preparing same
KR101663326B1 (ko) 천식, copd, 알레르기성 비염, 알레르기성 결막염, 아토피성 피부염, 암, b형 간염, c형 간염, hiv, hpv, 박테리아 감염 및 피부병의 치료를 위한 피리미딘 유도체
US2430439A (en) Sulfonamido pyrimidines
US20040186118A1 (en) Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US20120040955A1 (en) Fluoro substituted pyrimidine compounds as jak3 inhibitors
KR20100016289A (ko) 면역-조정 특성의 이미다조퀴놀린
NO324952B1 (no) Nye sulfonamider, fremstilling av disse, farmasoytiske preparater inneholdende slike,anvendelse av disse forbindelsene som medikament samt anvendelse av disse for fremstilling av medikament for behandling av lidelser.
KR20080017382A (ko) Gaba b 매개된 신경계 장애 치료용 피리미딘 유도체
EP0168262A2 (en) Pyrimidine derivatives, processes for preparation thereof and use thereof
US2691655A (en) 2-amino-4-substituted amino-6-aryl pyrimidines and process of preparing same
JPS6354714B2 (da)
EP0580753B1 (en) Pyrimidine derivatives for enhancing antitumor activity
CN100562518C (zh) 芳乙烯磺胺类化合物
US4666915A (en) 2-anilino-1,6-dihydro-6-oxo-5-pyrimidine-carboxylic acid derivatives, process for the preparation thereof, and antiallergic agent containing the same
US3432493A (en) Substituted sulfanilamides
JP3252502B2 (ja) N−5保護した2,5−ジアミノ−4,6−ジクロロピリミジンおよびその製造方法
US2465568A (en) Pyrimidine compounds
DE2937023A1 (de) Neue substituierte 5-(2-imidazolin-2-yl)-aminopyrimidine und verfahren zu deren herstellung
SE449101B (sv) 1-bensyl-4-/4-(2-pyrimidinylamino)bensyl/-2,3-dioxopiperazinderivat, forfarande for framstellning derav och karcinostatiska medel der de ingar
CA1152074A (en) Pyrimidyl thioureas
US4434167A (en) Pyrimidyl thioureas useful for the treatment of hypertension and hyperlipidemia
US2437682A (en) Pyrimidine compounds and processes

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7909392-8

SPCF Application for supplementary protection certificate filed

Free format text: 9990012, 981023

SPCG Supplementary protection certificate granted

Free format text: 9990012, 981023, EXPIRES: 20041114

NUG Patent has lapsed

Ref document number: 7909392-8